)

Praxis Precision Medicines (PRAX) investor relations material
Praxis Precision Medicines H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key clinical data and physician feedback
Recent data from the Radiant study of Matrigene showed significant seizure reduction and favorable tolerability, generating strong excitement among clinicians at the International Epilepsy Congress.
Physicians highlighted the rapid onset of effect, depth of response, and positive side effect profile, especially in a difficult-to-treat patient population.
Operational learnings from Radiant led to improved patient counseling and lower discontinuation rates in ongoing Power One trials.
No protocol or statistical plan changes were made to Power One, but operational adjustments improved trial execution.
Feedback indicated a need for better discontinuation management, which is being addressed in current studies.
Market opportunity and commercial outlook
The refractory epilepsy market is vast, with 1–2 million U.S. patients switching therapies annually and significant unmet needs even among those considered controlled.
Many patients on monotherapy experience life-limiting side effects, highlighting a broader market beyond refractory cases.
Commercial focus is shifting as new drugs demonstrate clear patient benefit, with expectations of significant market expansion.
The company anticipates NDA submission for Matrigene after Power One and Power Two readouts, with Power Three potentially supporting a broader label.
Strong site and investigator interest is accelerating trial enrollment and timelines.
Pipeline progress and regulatory milestones
Power One is finalizing recruitment this year, Power Two is starting in Q3, and both may have readouts next year, supporting a near-term NDA submission.
Power Three, a monotherapy study, is expected to enroll quickly and could provide unique label claims at launch.
Religiogene, targeting rare epilepsies, showed a 90% reduction in seizures in the latest update and received FDA breakthrough designation.
The registration cohort for Religiogene is substantially complete, potentially enabling accelerated approval discussions with the FDA.
The company is targeting pediatric disease designation and aims to secure a priority review voucher by September 2026.
Next Praxis Precision Medicines earnings date

Next Praxis Precision Medicines earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage